#TwitteRx 🦠Our ID PGY2 is entering its 10th year! 🧫 #IDTwitter
Join a legacy of excellence in training & professional placement!
Features:
💊Abx Stewardship
💊ID Consults
💊Microbiology
💊OPAT
💊HIV/AIDS
💊SOT
💊Infection Control
💊Research
💊Teaching
💊Harvard didactics
🚨 New outpatient/OPAT ID pharmacist position at @TuftsMedicalCtr @tufts_id 🚨
Come join the wonderful world of OPAT & get added to the Boston ID PharmD google sheet (you know I love a good google sheet!) @SIDPharm@accpinfdprn
https://t.co/InpGEZqKxt
#TwitteRx#IDTwitter
UPDATE: We are converting our international PGY1 spot into a general PGY1 spot for Phase II of the #RxMatch2022
We will have one PGY1 position open during Phase II! Please DM us or our RPD (@NickEdmonds13) with any questions!
@ASHPOfficial@MAPharmacists#TwitteRx#PharmRes
Yes, tis true! We are heading into phase 2 to fill our 2nd PGY2 ID position. I'll be seeing some of you via zoom in the upcoming weeks! Please apply if interested! #TwitteRx#IDTwitter
It's offensive that the AMA chose Biden's Test-to-Treat COVID-19 plan as an opportunity to double down on their "scope creep" messaging and to take a swipe at pharmacists, when in fact, it's pharmacists that are *the* experts on drug-drug interactions.
@AndreaSikora@uncrx_critcare Nice! Also a big fan of “absence of evidence of harm does not constitute evidence of absence”, will have to start using that one 🤔